Morgan Stanley Discloses Major Crypto Holdings in SEC Filing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 29 2026
0mins
Source: Yahoo Finance
- Increased Crypto Holdings: Morgan Stanley disclosed significant holdings in Bitcoin, Solana, and XRP in its Q1 2026 SEC 13F filing, reflecting its ongoing interest and confidence in the crypto market.
- Institutional Investment Surge: The filing indicates that Morgan Stanley has substantially increased its institutional exposure to cryptocurrencies through regulated exchange-traded products, signaling an accelerated strategic positioning in the digital asset space.
- Bitcoin ETF Investments: The firm invested over $861 million across various Bitcoin ETFs, particularly in the iShares Bitcoin Trust ETF and Fidelity Wise Origin Bitcoin Fund, demonstrating a strong bullish outlook on Bitcoin.
- Clear Competitive Strategy: Morgan Stanley has filed with the SEC to launch a low-fee spot Bitcoin ETF, aiming to compete aggressively with industry giants like BlackRock and Grayscale, thereby reinforcing its leadership in cryptocurrency investments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MS
Wall Street analysts forecast MS stock price to fall
14 Analyst Rating
7 Buy
7 Hold
0 Sell
Moderate Buy
Current: 222.100
Low
132.00
Averages
185.00
High
219.00
Current: 222.100
Low
132.00
Averages
185.00
High
219.00
About MS
Morgan Stanley is a global financial services company. The Company is engaged in providing a range of investment banking, securities, wealth management and investment management services. Its segments include Institutional Securities, Wealth Management and Investment Management. Its Institutional Securities segment provides a variety of products and services to corporations, governments, financial institutions and ultra-high net worth clients. Its Wealth Management segment provides an array of financial services and solutions to individual investors and small to medium-sized businesses and institutions. Its Investment Management segment provides a range of investment strategies and products that span geographies, asset classes, and public and private markets to a diverse group of clients across institutional and intermediary channels. Its investment banking services consist of capital raising and financial advisory services, including the underwriting of debt and other products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Morgan Stanley Invests in 932 MW Power Project
- Investment Overview: Morgan Stanley Infrastructure Partners announces an investment in the 932-megawatt gas-fired combined cycle power generation project, Greenlight, located in Sturgeon County, Alberta, reflecting its strategic focus on North American electricity markets.
- Ownership Structure: Morgan Stanley and Pembina Pipeline Corporation will each hold a 47.5% stake in the Greenlight project, while Kineticor Asset Management retains the remaining 5%, facilitating effective project management and execution.
- Market Demand Response: The project is expected to provide long-term, reliable power to meet the growing electricity demand driven by artificial intelligence and data centers, further solidifying Morgan Stanley's position in critical infrastructure investments.
- Construction Management Advantage: Pembina will serve as the construction and operations manager, leveraging its local expertise in delivering large-scale infrastructure projects to ensure the efficient implementation and operation of the Greenlight project.
See More
Bank of America Passes Stress Test, Stock Rises
- Strong Stress Test Results: Bank of America excelled in the Fed's 2026 stress tests, being one of 32 financial institutions to pass, which led to a stock price increase of over 10% in June, instilling confidence in investors and indicating future dividend growth.
- Launch of New Payment Product: The bank introduced a new cross-border real-time payments product designed for high-volume, low-value transfers, with expectations that P2P payment demand will rise by 58% and B2C by 132% by 2032, potentially increasing the bank's market share.
- Dividend Growth Expectations: While Bank of America is cautious about announcing dividend increases, the market anticipates it will follow other major banks in raising dividends by at least 10%, which will enhance investor confidence and attract more capital inflows.
- Analyst Price Target Increases: Analysts from Morgan Stanley and Truist Securities raised their price targets for Bank of America to $67 and $64 respectively, both maintaining buy ratings, reflecting optimistic market expectations for the bank's future performance.
See More
Federal Reserve Stress Test Results Favor Bank of America
- Strong Stress Test Performance: Bank of America excelled in the Federal Reserve's 2026 stress tests, being one of the 32 financial institutions to pass, which is expected to lead to a dividend increase, further attracting investor interest.
- Significant Stock Price Increase: Following the positive stress test results, Bank of America's stock rose over 10% in June, reflecting market confidence in its financial health and enhancing its position in a competitive financial landscape.
- Launch of New Payment Product: Bank of America introduced a new cross-border real-time payments product designed for high-volume, low-value transfers, with P2P and B2C payment demand projected to grow by 58% and 132% by 2032, respectively, which will further enhance its market share.
- Analyst Price Target Increases: Analysts from Morgan Stanley and Truist Securities raised their price targets for Bank of America to $67 and $64, respectively, indicating a positive outlook on its future performance and reinforcing investor confidence.
See More
Vertex Acquires Crinetics for $10 Billion
- Acquisition Scale: Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $85 per share in cash, totaling approximately $10 billion, with the deal expected to close in Q3 2026, marking a significant step for Vertex into a new disease area.
- Asset Value of Crinetics: Crinetics brings the drug PALSONIFY, the first approved once-daily oral therapy for adults with acromegaly, which is expected to fill a market gap; combined with other drugs, Crinetics' assets have a peak sales potential exceeding $5 billion annually.
- Financing Structure Analysis: The acquisition will be financed through a mix of cash and debt, with Vertex planning to utilize $4.5 billion in bridge financing alongside its $13 billion in cash and marketable securities, ensuring the feasibility of the acquisition without over-leveraging.
- Strategic Significance and Future Outlook: Although Vertex expects the deal to contribute to non-GAAP operating income only by 2029, this acquisition aligns with its strategy targeting serious diseases, addressing the company's diversification needs and signaling growth potential in new areas.
See More
Vertex Acquires Crinetics for $85 Per Share in Cash
- Acquisition Overview: Vertex has agreed to acquire Crinetics for $85 per share in cash, totaling approximately $10 billion in equity value, with the deal expected to close in Q3 2026, marking a significant expansion into a new disease area for Vertex.
- New Drug Assets: Crinetics brings PALSONIFY, the first and only once-daily oral therapy approved for acromegaly, which is expected to fill a market gap; combined with other candidates, these assets boast over $5 billion in peak sales potential.
- Financing Structure: The acquisition will be funded through a mix of cash on hand and debt, with Vertex securing $4.5 billion in bridge financing, while holding approximately $13 billion in cash and marketable securities, indicating strong financial health.
- Strategic Implications: This acquisition not only provides Vertex with a new growth engine to meet diversification needs but also aligns with its strategy of targeting serious diseases, with positive impacts on adjusted operating income anticipated by 2029.
See More
Wall Street's Major Banks Bullish on SpaceX's Future
- Analysts' Optimistic Outlook: Deutsche Bank analysts describe SpaceX as 'the apex of civilizational ambition,' indicating strong confidence in the company's future role in shaping history and technological advancement.
- Market Capitalization: With a market cap of $2.1 trillion and a closing price of $160.42 per share on Monday, SpaceX's performance post-IPO reflects market approval, although MoffettNathanson remains pessimistic about its value over the next 12 months.
- Technological Innovation Potential: Analysts at Raymond James assert that the successful deployment of Starship will industrialize orbital transportation, potentially reducing launch costs to hundreds of dollars per kilogram, thereby advancing the broader space economy.
- Diversified Business Strategy: SpaceX's integration strategy across its three business segments—Space, Connectivity, and Artificial Intelligence—is expected to enhance its competitive edge in future markets, particularly as Starlink's user base has reached 12 million, becoming a significant revenue driver.
See More
Morgan Stanley Invests in 932 MW Power Project
- Investment Overview: Morgan Stanley Infrastructure Partners announces an investment in the 932-megawatt gas-fired combined cycle power generation project, Greenlight, located in Sturgeon County, Alberta, reflecting its strategic focus on North American electricity markets.
- Ownership Structure: Morgan Stanley and Pembina Pipeline Corporation will each hold a 47.5% stake in the Greenlight project, while Kineticor Asset Management retains the remaining 5%, facilitating effective project management and execution.
- Market Demand Response: The project is expected to provide long-term, reliable power to meet the growing electricity demand driven by artificial intelligence and data centers, further solidifying Morgan Stanley's position in critical infrastructure investments.
- Construction Management Advantage: Pembina will serve as the construction and operations manager, leveraging its local expertise in delivering large-scale infrastructure projects to ensure the efficient implementation and operation of the Greenlight project.
See More
Bank of America Passes Stress Test, Stock Rises
- Strong Stress Test Results: Bank of America excelled in the Fed's 2026 stress tests, being one of 32 financial institutions to pass, which led to a stock price increase of over 10% in June, instilling confidence in investors and indicating future dividend growth.
- Launch of New Payment Product: The bank introduced a new cross-border real-time payments product designed for high-volume, low-value transfers, with expectations that P2P payment demand will rise by 58% and B2C by 132% by 2032, potentially increasing the bank's market share.
- Dividend Growth Expectations: While Bank of America is cautious about announcing dividend increases, the market anticipates it will follow other major banks in raising dividends by at least 10%, which will enhance investor confidence and attract more capital inflows.
- Analyst Price Target Increases: Analysts from Morgan Stanley and Truist Securities raised their price targets for Bank of America to $67 and $64 respectively, both maintaining buy ratings, reflecting optimistic market expectations for the bank's future performance.
See More
Federal Reserve Stress Test Results Favor Bank of America
- Strong Stress Test Performance: Bank of America excelled in the Federal Reserve's 2026 stress tests, being one of the 32 financial institutions to pass, which is expected to lead to a dividend increase, further attracting investor interest.
- Significant Stock Price Increase: Following the positive stress test results, Bank of America's stock rose over 10% in June, reflecting market confidence in its financial health and enhancing its position in a competitive financial landscape.
- Launch of New Payment Product: Bank of America introduced a new cross-border real-time payments product designed for high-volume, low-value transfers, with P2P and B2C payment demand projected to grow by 58% and 132% by 2032, respectively, which will further enhance its market share.
- Analyst Price Target Increases: Analysts from Morgan Stanley and Truist Securities raised their price targets for Bank of America to $67 and $64, respectively, indicating a positive outlook on its future performance and reinforcing investor confidence.
See More
Vertex Acquires Crinetics for $10 Billion
- Acquisition Scale: Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $85 per share in cash, totaling approximately $10 billion, with the deal expected to close in Q3 2026, marking a significant step for Vertex into a new disease area.
- Asset Value of Crinetics: Crinetics brings the drug PALSONIFY, the first approved once-daily oral therapy for adults with acromegaly, which is expected to fill a market gap; combined with other drugs, Crinetics' assets have a peak sales potential exceeding $5 billion annually.
- Financing Structure Analysis: The acquisition will be financed through a mix of cash and debt, with Vertex planning to utilize $4.5 billion in bridge financing alongside its $13 billion in cash and marketable securities, ensuring the feasibility of the acquisition without over-leveraging.
- Strategic Significance and Future Outlook: Although Vertex expects the deal to contribute to non-GAAP operating income only by 2029, this acquisition aligns with its strategy targeting serious diseases, addressing the company's diversification needs and signaling growth potential in new areas.
See More
Vertex Acquires Crinetics for $85 Per Share in Cash
- Acquisition Overview: Vertex has agreed to acquire Crinetics for $85 per share in cash, totaling approximately $10 billion in equity value, with the deal expected to close in Q3 2026, marking a significant expansion into a new disease area for Vertex.
- New Drug Assets: Crinetics brings PALSONIFY, the first and only once-daily oral therapy approved for acromegaly, which is expected to fill a market gap; combined with other candidates, these assets boast over $5 billion in peak sales potential.
- Financing Structure: The acquisition will be funded through a mix of cash on hand and debt, with Vertex securing $4.5 billion in bridge financing, while holding approximately $13 billion in cash and marketable securities, indicating strong financial health.
- Strategic Implications: This acquisition not only provides Vertex with a new growth engine to meet diversification needs but also aligns with its strategy of targeting serious diseases, with positive impacts on adjusted operating income anticipated by 2029.
See More
Wall Street's Major Banks Bullish on SpaceX's Future
- Analysts' Optimistic Outlook: Deutsche Bank analysts describe SpaceX as 'the apex of civilizational ambition,' indicating strong confidence in the company's future role in shaping history and technological advancement.
- Market Capitalization: With a market cap of $2.1 trillion and a closing price of $160.42 per share on Monday, SpaceX's performance post-IPO reflects market approval, although MoffettNathanson remains pessimistic about its value over the next 12 months.
- Technological Innovation Potential: Analysts at Raymond James assert that the successful deployment of Starship will industrialize orbital transportation, potentially reducing launch costs to hundreds of dollars per kilogram, thereby advancing the broader space economy.
- Diversified Business Strategy: SpaceX's integration strategy across its three business segments—Space, Connectivity, and Artificial Intelligence—is expected to enhance its competitive edge in future markets, particularly as Starlink's user base has reached 12 million, becoming a significant revenue driver.
See More
